Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease

AIDS

Volumn 12, Issue 7, 1998, Pages 745-750

  Piketty, Christophe ^a   Castiel, Philippe ^a   Belec, Laurent ^a   Batisse, Dominique ^a   Mohamed, Ali Si ^a   Gilquin, Jacques ^a   Gonzalez Canali, Gustavo ^a   Jayle, Didier ^a   Karmochkine, Marina ^a   Weiss, Laurence ^a   Aboulker, Jean Pierre ^b   Kazatchkine, Michel D ^a  

^a HÔPITAL BROUSSAIS   (France)

^b INSERM   (France)

Author keywords

AIDS; Antiretroviral therapy; CD4 cells; HIV; HIV RNA; Indinavir; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 7144229335     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199807000-00011     Document Type: Article

References (15)

1. Gulick RM, Mellors J, Havlir D, et al.: Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
2. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogs plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. 3. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract LB7].
4. Cameron B, Heath-Chiozzi M, Kravei S, et al.: Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB411].
5. Kopp JB, Miller KD, Mican JAM, et al.: Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997, 127:119-125.
6. Hughes MD, Johnson VA, Hirsch MA, et al.: Monitoring plasma HIV-1 levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997, 126:929-938.
7. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
8. O'Brien WA, Hartigan PM, Daar ES, et al.: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
9. Brun-Vézinet F, Boucher C, Loveday C, et al.: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta study. Lancet 1997, 350:983-990.
10. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med 1996, 335:1091-1098.
11. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996, 335:1081-1090.
12. Coombs RW, Welles SL, Hooper C, et al.: Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS clinical trials group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis 1996, 174:704-712.
13. Eron JE, Benoit SL, Jensek J, et al.: Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200-500 CD4 cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
14. Kempf Dj, Marsh KC, Paul DA, et al.: Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicob Agents Chemother 1991, 35:2209-2214.
15. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997, 387:188-191.